tbuckley/cabot-search huggingface dataset:
OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
Authors: C. Langer, S. Gadgeel, H. Borghaei, A. Patnaik, S. Powell, R. Gentzler, J.C. Yang, M. Gubens, L. Sequist, M. Awad, R. Cristescu, D. Aurora-Garg, A. Albright, A. Loboda, J. Kobie, J. Lunceford, M. Ayers, G. Lubiniecki, B. Piperdi, M.C. Pietanza, V. Papadimitrakopoulou
Journal: Journal of Thoracic Oncology (2019)
Social Outcomes after High Dose Chemotherapy with Autologous Stem Cell Transplant
Authors: Bente Arboe, Jette Soenderskov Goerloev, Maja Halgren Olsen, Susanne Oksbjerg Dalton, Kristina Fruerlund Nielsen, Soeren Ramme Nielsen, Charlotte Madsen, Rasmus Nielsen, Peter de Nully Brown
Journal: Blood (2016)
P2.04-41 Clinical and Immunological Factors Associated with Mutation Burden in Non-Small Cell Lung Cancer
Authors: Y. Terada, A. Ono, M. Isaka, T. Kawata, M. Serizawa, T. Kawabata, T. Imai, K. Muramatsu, I. Hayashi, H. Kenmotsu, M. Kusuhara, Y. Akiyama, K. Yamaguchi, T. Sugino, Y. Ohde, T. Takahashi
Journal: Journal of Thoracic Oncology (2019)
P2.01-49 Targeting STAT3-Positive Reactive Astrocytes with Silibinin in the Therapeutic Landscape of Non-Small-Cell Lung Cancer with Brain Metastases
Authors: J. Bosch-Barrera, N. Priego, M. Puigdemont, E. Sais, N. Quer, A. Izquierdo, A. Hernandez, E. Cuyàs, A. Carbó, E. Teixidor, S. Verdura, D. Garcia, A. Roselló, V. Garriga, S. Pedraza, J. Brunet, A. Calvo, J. Menéndez, M. Valiente
Journal: Journal of Thoracic Oncology (2019)
Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends (1995–2015)
Authors: Cari M Kitahara, Ruth M Pfeiffer, Julie A Sosa, Meredith S Shiels
Journal: JNCI Journal of the National Cancer Institute (2019)

Abstract Background Since the early 1980s, papillary thyroid cancer (PTC) incidence rates and the prevalence of obesity, a risk factor for PTC, have increased substantially in the United States. We estimated the proportion of PTC incidence in the United States attributable to overweight and obesity during 1995–2015. Methods National Institutes of Health-AARP Diet and Health Study cohort data (n = 457 331 participants, 50–71 years and cancer-free at baseline) were used to estimate multivariable-adjusted hazard ratios (HRs) for PTC across body mass index categories. Population attributable fractions (PAFs) were calculated using estimated hazard ratios and annual overweight and obesity prevalence estimates from the National Health Interview Survey. PAF estimates were combined with Surveillance, Epidemiology, and End Results-13 data to calculate annual percent changes in PTC incidence rates attributable (and unrelated) to overweight and obesity. Results Overweight (25.0–29.0 kg/m2) and obesity (≥30.0 kg/m2) were associated with 1.26-fold (95% confidence interval [CI] = 1.05- to 1.52-fold) and 1.30-fold (95% CI = 1.05- to 1.62-fold) increased risks of PTC, respectively, and nearly threefold (HR = 2.93, 95% CI = 1.25 to 6.87) and greater than fivefold (HR = 5.42, 95% CI = 2.24 to 13.1) increased risks of large (&amp;gt;4 cm) PTCs compared with normal weight (18.5–24.9 kg/m2). During 1995–2015, PAF estimates for overweight and obesity increased from 11.4% to 16.2% for all PTCs and from 51.4% to 63.2% for large PTCs. Overweight or obesity accounted for 13.6% and 57.8% of the annual percent changes in total (5.9%/y) and large (4.5%/y) PTC incidence rates, respectively, during 1995–2015. Conclusions Overweight and obesity may have contributed importantly to the rapid rise in PTC incidence during 1995–2015. By 2015, we estimate that one of every six PTCs diagnosed among adults 60 years or older, including nearly two-thirds of large PTCs, were attributable to overweight and obesity.
P1.16-27 Risk Factors Associated with a Second Primary Lung Cancer (SPLC) in Patients (Pts) with an Initial Primary Lung Cancer (IPLC)
Authors: M. Nagasaka, D. Farhat, K. Belzer, S. Kim, M.A. Milczuk, H. Mamdani, A. Sukari, A. Wozniak
Journal: Journal of Thoracic Oncology (2019)
EP1.14-11 Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Authors: C. Alfaro Autor, A. Romero, V. Calvo De Juan, F. Franco, E. Sánchez Romero, N. Ortiz Cortes, S. Sanz Moreno, A. Rodríguez Festa, R. Serna Blasco, M. Barquín Del Romo, M. Provencio
Journal: Journal of Thoracic Oncology (2019)
Risk of coronary artery disease according to glucose abnormality status and prior coronary artery disease in Japanese men
Authors: Masaru Kitazawa, Kazuya Fujihara, Taeko Osawa, Masahiko Yamamoto, Mayuko Harada Yamada, Masanori Kaneko, Yasuhiro Matsubayashi, Takaho Yamada, Nauta Yamanaka, Hiroyasu Seida, Hirohito Sone
Journal: Metabolism (2019)
P1.18-06 Efficacy and Safety of Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Non-Small Cell Lung Cancer
Authors: N. Li, J. Ying, X. Tao, F. Zhang, Z. Zhao, Y. Ling, Y. Gao, J. Zhao, Q. Xue, Y. Mao, W. Lei, N. Wu, S. Wang, J. Duan, Y. Gao, Z. Wang, N. Sun, J. Wang, S. Gao, J. He, H. Zhou, S. Wang
Journal: Journal of Thoracic Oncology (2019)
P1.03-01 Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in NSCLC
Authors: S.H. Choi, J. Park, S.K. Do, J.E. Choi, J.Y. Jeong, S.S. Yoo, S.Y. Lee, E. Lee, J.Y. Park
Journal: Journal of Thoracic Oncology (2019)
P2.09-05 Clinical and Biological Characterization of Lung Enteric Adenocarcinoma
Authors: G. Galli, M. Imbimbo, A. Busico, F. Perrone, E. Tamborini, A. Fabbri, G. Marano, D. Biganzoli, R. Ferrara, G. Lo Russo, A. Prelaj, C. Proto, N. Zilembo, A. De Toma, F. Pagani, G. Randon, M. Ganzinelli, E. Biganzoli, G. Pruneri, F. De Braud, M. Garassino, D. Signorelli
Journal: Journal of Thoracic Oncology (2019)
P2.01-68 High NLR Is Poor Predictive Biomarker for NSCLC Treated with PD-1 Inhibitor in Real World Practice
Authors: S.S. Cho, S.K. Kim, H.S. Park, H.J. An, K.D. Cho, D.G. Cho, Y.H. Park, J. Yoo, S.W. Kim, J.M. Ko, Y.S. Hwang, G.R. Heo, C.H. Kim, B.Y. Shim, E.J. Park
Journal: Journal of Thoracic Oncology (2019)
EP1.11-20 A Panel of Liquid Biomarkers for Early Response Capturing of NSCLC Therapies in Advanced Stages
Authors: F. Janke, M. Schneider, S. Wrenger, S. Dietz, T. Muley, G. Heussel, C. Heussel, C. Da Silva, F. Bozorgmehr, S. Janciauskiene, H. Sültmann, M. Meister
Journal: Journal of Thoracic Oncology (2019)
Pretransplant Kinetics of Anti-HLA Antibodies in Patients on the Waiting List for Kidney Transplantation
Authors: Matteo Togninalli, Daisuke Yoneoka, Antonios G.A. Kolios, Karsten Borgwardt, Jakob Nilsson
Journal: Journal of the American Society of Nephrology (2019)

Patients on organ transplant waiting lists are evaluated for preexisting alloimmunity to minimize episodes of acute and chronic rejection by regularly monitoring for changes in alloimmune status. There are few studies on how alloimmunity changes over time in patients on kidney allograft waiting lists, and an apparent lack of research-based evidence supporting currently used monitoring intervals.To investigate the dynamics of alloimmune responses directed at HLA antigens, we retrospectively evaluated data on anti-HLA antibodies measured by the single-antigen bead assay from 627 waitlisted patients who subsequently received a kidney transplant at University Hospital Zurich, Switzerland, between 2008 and 2017. Our analysis focused on a filtered dataset comprising 467 patients who had at least two assay measurements.Within the filtered dataset, we analyzed potential changes in mean fluorescence intensity values (reflecting bound anti-HLA antibodies) between consecutive measurements for individual patients in relation to the time interval between measurements. Using multiple approaches, we found no correlation between these two factors. However, when we stratified the dataset on the basis of documented previous immunizing events (transplant, pregnancy, or transfusion), we found significant differences in the magnitude of change in alloimmune status, especially among patients with a previous transplant versus patients without such a history. Further efforts to cluster patients according to statistical properties related to alloimmune status kinetics were unsuccessful, indicating considerable complexity in individual variability.Alloimmune kinetics in patients on a kidney transplant waiting list do not appear to be related to the interval between measurements, but are instead associated with alloimmunization history. This suggests that an individualized strategy for alloimmune status monitoring may be preferable to currently used intervals.
Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) <i>SMARCB1</i> in NENS of colorectal origin using next-generation sequencing (NGS).
Authors: Jaume Capdevila, Stefania Landolfi, Jose Jimenez, Enrique Grande, Daniel E. Castellano, Jorge Barriuso, Cristina Teixido, Daniel Silberschmidt, Maria Angeles Montero, Hector G. Palmer, Enriqueta Felip, Josep Tabernero, Ana Vivancos
Journal: Journal of Clinical Oncology (2013)

4135 Background: The knowledge of molecular aberrations that characterize the different types of NENS is still limited. Recent exome sequencing data has allowed the definition of the genetic basis of pancreatic NENS. We aimed to define the tumor genomic profiling in non-pancreatic NENS using NGS. Methods: FFPE samples from NENS of different non-pancreatic origins were analyzed. A single pathologist evaluated them for tumor content (cutoff &gt;30% tumor cells) and lymphocyte infiltration. DNA was obtained and quality assessed by a qPCR-based method. We performed amplicon-seq using 476 primer pairs targeting hotspot mutation loci in oncogenes as well as TSG. An initial amplification step was performed, amplicon sizes ranging 80-120 bp. After that, 100 ng of dsDNA were used for standard indexed TruSeq Genomic sample preparation. Samples were pooled in two groups and sequenced in a MiSeq instrument (Illumina) in a 2X100 run. Reads were aligned (BWA), variants called (GATK) and annotated. Final individual manual check of mutations was performed. NENS types were classified following the 2010 WHO classification. Results: We analyzed 38 NENS samples of different origins and grades: 7 G3 colon, 8 G1/2 colon, 8 G1/2 ileum, 8 G1/2 gastric, and 7 G1/2 lung. We identified 24 mutations in several genes and different distribution regarding tumor origin was observed. G3 colon NENS presented mutations in KRAS (43%), APC (28%), and VHL (14%). Ileum NENS showed mutations in TP53 (50%), VHL (37%), FGFR3 (12%) and APC (12%). In G1/2 NENS of colon origin, mutations in SMARCB1 (37%), KRAS (12%) and NF2 (12%) were identified. Less frequent mutations were present in gastric and lung samples (KRAS, TP53 and FGFR3 in 12% each). Conclusions: A tumor origin specific mutation pattern has been observed for NENS. To our knowledge this is the first time to describe mutations in SMARCB1 TSG in this setting. Further investigation is warranted to define the role of SMARCB1 in the pathogenesis of NENS.
Sick Individuals and Sick (Microbial) Populations: Challenges in Epidemiology and the Microbiome
Authors: Audrey Renson, Pamela Herd, Jennifer B. Dowd
Journal: Annual Review of Public Health (2019)

The human microbiome represents a new frontier in understanding the biology of human health. While epidemiology in this area is still in its infancy, its scope will likely expand dramatically over the coming years. To rise to the challenge, we argue that epidemiology should capitalize on its population perspective as a critical complement to molecular microbiome research, allowing for the illumination of contextual mechanisms that may vary more across populations rather than among individuals. We first briefly review current research on social context and the gut microbiome, focusing specifically on socioeconomic status (SES) and race/ethnicity. Next, we reflect on the current state of microbiome epidemiology through the lens of one specific area, the association of the gut microbiome and metabolic disorders. We identify key methodological shortcomings of current epidemiological research in this area, including extensive selection bias, the use of noncompositionally robust measures, and a lack of attention to social factors as confounders or effect modifiers.
P2.12-01 Small Cell Lung Cancer (SCLC) Treatment and Survival in the UK: A REAL-Oncology Analysis from the I-O Optimise Initiative
Authors: M. Snee, S. Cheeseman, M. Thompson, R. Bowman, L. Lacoin, W. Sopwith, C. Chaib, A. Juarez-Garcia, M. Daumont, J. Penrod, J. O'Donnell, G. Hall
Journal: Journal of Thoracic Oncology (2019)
IBS06.01 Realtime Data from Europe ETOP / ESTS Database
Authors: I. Opitz, A. Bille, Z. Tsourti, K. Nakaerts, L. Ampollini, M. De Perrot, L. Brcic, E. Nadal, S. Gray, J. Aerts, E. Verbeken, E. Silini, F. Zaeimi, M. Samarzija, R. Llatjos, S. Tsimpoukis, J.H. Van Der Thüsen, S. Finn, N. Marti, G. Dimopoulou, K. Monkhorst, A. Brunello, R. Kammler, A. Soltermann, P. Falcoz, P. Baas, R. Stahel, F. Etop Mesoscape, F. Ests Consortia
Journal: Journal of Thoracic Oncology (2019)
P2.12-22 Risk Factors for BM Incidence in SCLC: A Predictive Model for SCLC Patients on Brain Metastasis
Authors: J. Zhang, H. Li, Q. Chen, C. Wu, H. Pan, Y. Pan, J. Zheng, J. Wen, L. Ouyang, C. Zhou
Journal: Journal of Thoracic Oncology (2019)
P1.01-05 Phase I Study of Inhaled 5-Azacytidine (5-Aza) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: H. Cheng, N. Fan, Y. Zou, C. Shah, B. Halmos, T. Bhagat, R. Gucalp, B. Piperdi, M. Kim, A. Verma, S. Spivack, R. Perez-Soler
Journal: Journal of Thoracic Oncology (2019)
P1.14-62 Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIIb Studies
Authors: F. De Marinis, H. Tu, K.K. Laktionov, A. Poltoratskiy, J. Zhao, I. Egorova, E. Tan, M. Gottfried, V. Lee, D. Kowalski, C. Yang, B. Srinivasa, A. Passaro, L. Clementi, W. Tang, D.C. Huang, A. Cseh, C. Zhou, Y. Wu
Journal: Journal of Thoracic Oncology (2019)
P2.11-06 Serum Proteomic Signature as a Potential Biomarker for Survival in Patients with NSCLC Receiving Immunotherapy
Authors: W.B. Kim, P. Viveiros, J. Anker, N. Simon, K. Rhee, J. Song, A. Cho, S. Chang, T. Ko, M. Oh, A. Davis, L.C. Park, Y.K. Chae
Journal: Journal of Thoracic Oncology (2019)
P1.18-25 The Impact of Radiation Pneumonitis on Prognosis of Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy
Authors: T. Akita, K. Baba, H. Tanaka, I. Fujioka, S. Suzuki, C. Tabe, T. Shiratori, Y. Ishioka, Μ. Itoga, K. Taima, J. Yokouchi, Y. Hasegawa, S. Takanashi, S. Tasaka
Journal: Journal of Thoracic Oncology (2019)
P2.08-04 Stereotactic Ablative Radiation Therapy to Lung Metastases Associates with Better Outcomes in Oligometastatic Lung Cancer: Prospective Study
Authors: M. Blake-Cerda, F. Lozano Ruiz, F. Maldonado Magos, D. De La Mata-Moya, D.A. Diaz-Garcia, L. Ramírez-Tirado, M.F. Cuevas Góngora, F. Barrón, R. Gerson, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
P1.11-07 CfDNA from Bronchoalveolar Lavage Fluid for the Identification of Solid Pulmonary Nodules: A New Medium of Liquid Biopsy
Authors: J. Jiang, C. Mu, J. Zhao, D. Zeng, C. Wang, H. Li, J. Ye, T. Zhang
Journal: Journal of Thoracic Oncology (2019)
Gains on Chromosome Band 9q34 Could Represent a Novel Independent Prognostic Marker in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Stem Cell Transplantation.
Authors: Peter Liebisch, Hartmut Goldschmidt, Kathrin Tschajka, Christiane Wendl, Axel Benner, Hartmut Dohner
Journal: Blood (2004)
Integrin-Linked Kinase Deficiency in Collecting Duct Principal Cell Promotes Necroptosis of Principal Cell and Contributes to Kidney Inflammation and Fibrosis
Authors: Ming Huang, Shuai Zhu, Huihui Huang, Jinzhao He, Kenji Tsuji, William W. Jin, Dongping Xie, Onju Ham, Diane E. Capen, Weining Lu, Teodor G. Păunescu, Baoxue Yang, Hua A. Jenny Lu
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement Necroptosis has emerged as an important cell death pathway that contributes to inflammation and injury of many organs, including the kidney. The mechanisms underlying necroptosis are not well understood. The authors have identified a previously unrecognized important role of integrin-linked kinase (ILK) in mediating necroptosis in collecting duct epithelial cell using genetically engineered mice to lack Ilk in the collecting duct principal cells of the kidney. These Ilk -knockout mice develop acute tubular injury, interstitial fibrosis and inflammation in the kidneys. Treating both the ILK inhibited cultured cells and ILK-deficient mice with a necroptosis inhibitor, necrostatin-1, reduced the harmful effects associated with the loss of ILK. The study shows that ILK plays an important role in regulating necroptosis in kidney tubular cells. Background Necroptosis is a newly discovered cell death pathway that plays a critical role in AKI. The involvement of integrin-linked kinase (ILK) in necroptosis has not been studied. Methods We performed experiments in mice with an Ilk deletion in collecting duct (CD) principal cells (PCs), and cultured tubular epithelial cells treated with an ILK inhibitor or ILK siRNA knockdown. Results Ilk deletion in CD PCs resulted in acute tubular injury and early mortality in mice. Progressive interstitial fibrosis and inflammation associated with the activation of the canonical TGF- β signaling cascade were detected in the kidneys of the mice lacking ILK in the CD PCs. In contrast to the minimal apoptosis detected in the animals’ injured CDs, widespread necroptosis was present in ILK-deficient PCs, characterized by cell swelling, deformed mitochondria, and rupture of plasma membrane. In addition, ILK deficiency resulted in increased expression and activation of necroptotic proteins MLKL and RIPK3, and membrane translocation of MLKL in CD PCs. ILK inhibition and siRNA knockdown reduced cell survival in cultured tubular cells, concomitant with increased membrane accumulation of MLKL and/or phospho-MLKL. Administration of a necroptosis inhibitor, necrostatin-1, blocked cell death in vitro and significantly attenuated inflammation, interstitial fibrosis, and renal failure in ILK-deficient mice. Conclusions The study demonstrates the critical involvement of ILK in necroptosis through modulation of the RIPK3 and MLKL pathway and highlights the contribution of CD PC injury to the development of inflammation and interstitial fibrosis of the kidney.
EP1.01-83 Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations
Authors: Y. Yamada, H. Imai, H. Minemura, T. Sugiyama, K. Kaira, K. Kanazawa, T. Kasai, K. Minato, T. Kaburagi
Journal: Journal of Thoracic Oncology (2019)
Occupational Intervention Unnecessary to Treat Back Pain
Authors: Anita Slomski
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Generation of diffuse intrinsic pontine glioma mouse models by brainstem targeted in utero electroporation
Authors: Smruti K Patel, Rachel M Hartley, Xin Wei, Robin Furnish, Fernanda Escobar-Riquelme, Heather Bear, Kwangmin Choi, Christine Fuller, Timothy N Phoenix
Journal: Neuro-Oncology (2019)

Abstract Background Diffuse intrinsic pontine gliomas (DIPGs) are highly lethal childhood brain tumors. Their unique genetic makeup, pathological heterogeneity, and brainstem location all present challenges to treatment. Developing mouse models that accurately reflect each of these distinct features will be critical to advance our understanding of DIPG development, progression, and therapeutic resistance. The aim of this study was to generate new mouse models of DIPG, and characterize the role of specific oncogenic combinations in DIPG pathogenesis. Methods We used in utero electroporation (IUE) to transfect neural stem cells in the developing brainstem with PiggyBac DNA transposon plasmids. Combinations of PDGFB, PdgfraD842V, or PdgfraWT, combined with dominant negative Trp53 (DNp53) and H3.3K27M expression induced fully penetrant brainstem gliomas. Results IUE enabled the targeted transfection of brainstem neural stem cells. PDGFB + DNp53 + H3.3K27M induced the rapid development of grade-IV gliomas. PdgfraD842V + DNp53 + H3.3K27M produced slower forming grade-III gliomas. PdgfraWT + DNp53 + H3.3K27M produced high and low-grade gliomas with extended latencies. PDGFB, PdgfraD842V, and PdgfraWT DIPG models display unique histopathological and molecular features found in human DIPGs. Conclusion Brainstem targeted in utero electroporation provides a rapid and flexible system to generate diverse DIPG mouse models. Using IUE to investigate mutation and pathohistological heterogeneity of DIPG will provide a valuable tool for future genetic and preclinical studies.
EP1.18-01 Effectiveness of Video-Assisted Surgery and Pre-Operative Multi-Disciplinary Support for Preserving Respiratory Function
Authors: M. Kataoka, D. Okutani, H. Kawai, K. Watanabe, S. Harita, M. Baba, T. Okutani, T. Fujita, K. Suemori
Journal: Journal of Thoracic Oncology (2019)
Reflections on the Link Between Income During Childhood and Risk of Developing Schizophrenia
Authors: Richard G. Frank
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
P1.15-12 A Different Aspect to Tumor Size Dilemma in Thymoma's TNM Staging Classification
Authors: A. Kayi Cangir, T. Direk, B. Yenigün, A. Yücemen, G. Kocaman, Y. Kahya, S. Enön, S. Dizbay Sak
Journal: Journal of Thoracic Oncology (2019)
P1.07-15 Screening for Long Term Ototoxicity in Lung and Upper Aerodigestive Cancer Survivors Treated with Platinum Chemotherapy
Authors: S. Kooner, G. Liu, K. Hueniken, S. Lee, J. Harris, C. De Guia, E. Anokye-Yeboah, P. Chow, P. Bapat, W. Xu, D. Howell, I. Tymoshyk, A. Embleton
Journal: Journal of Thoracic Oncology (2019)